Keryx Biopharmaceuticals (KERX) 5.87 $KERX
Here's a One-of-a-Kind Stock Screen
at The Street - Wed Aug 19, 4:35PM CDT
And you don't even need a computer.
RST: 6.80 (+0.02), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Shares Down 50.3% Since SmarTrend's Sell Call (KERX)
Comtex SmarTrend(R) - Wed Aug 19, 11:10AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 5 months, Keryx Biopharmaceuticals has returned 50.27% as of today's recent price of $6.05.
KERX: 5.87 (+0.26)
4 Reasons to Sell Keryx Pharmaceuticals
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 18, 12:48PM CDT
For investors in Keryx Biopharmaceuticals (NASDAQ: KERX), a small-cap biotech with a focus on renal disease, 2015 hasn't been a good year, as its stock has plunged more than 50% since the start of the year. Despite being a company that holds ...
MS: 33.30 (+1.54), KERX: 5.87 (+0.26)
48.6% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Aug 12, 9:47AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 48.58% as of today's recent price of $6.25.
KERX: 5.87 (+0.26)
Downgrade Alert for Keryx Biopharmaceuticals (KERX)
Comtex SmarTrend(R) - Tue Aug 11, 7:00AM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $6.34 on volume of 2.4 million shares, above average daily volume of 1.8 million. Potential upside of 225.3% exists for Keryx Biopharmaceuticals, based on a current level of $6.34 and analysts' average consensus price target of $20.62. The stock should find initial resistance at its 50-day moving average (MA) of $9.30 and further resistance at its 200-day MA of $12.23.
KERX: 5.87 (+0.26)
Biotech Stock Mailbag: Controversial Stocks Revisited
at The Street - Fri Aug 07, 5:10AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RGLS: 7.20 (+0.42), RMTI: 11.58 (+0.43), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), KERX: 5.87 (+0.26)
Keryx Posts In-Line Loss in Q2, Auryxia in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 1:42PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) second-quarter 2015 loss of 26 cents per share was in line with the Zacks Consensus Estimate.
VRX: 227.24 (+7.16), ADHD: 7.84 (-0.02), ANAC: 132.24 (+6.60), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Has Returned 38.3% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Wed Aug 05, 9:23AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 38.30% as of today's recent price of $7.50.
KERX: 5.87 (+0.26)
Biotechnology Stocks Technical Data -- Keryx Biopharma, Idera Pharma, Synthetic Biologics, OvaScience and Infinity Pharma
PR Newswire - Wed Aug 05, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Synthetic Biologics Inc. (AMEX: SYN), OvaScience Inc. (NASDAQ: OVAS) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Keryx Biopharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=KERX. On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69 and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SYN: 2.25 (+0.03), OVAS: 20.83 (+1.80), IDRA: 2.83 (+0.14), INFI: 8.87 (+0.38), KERX: 5.87 (+0.26)
Keryx's (KERX) Q2 Loss in-Line with Estimates - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 7:29AM CDT
Keryx's (KERX) Q2 Loss in-Line with Estimates
KERX: 5.87 (+0.26)
Keryx Biopharma reports 2Q loss
Automated Insights - Wed Aug 05, 6:18AM CDT
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Wednesday reported a loss of $26.9 million in its second quarter.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
GlobeNewswire - Wed Aug 05, 6:00AM CDT
Majority of phosphate binder patients today have access to Auryxia(TM)
KERX: 5.87 (+0.26)
Why Keryx Biopharmaceuticals Stock Plunged 18% in July
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 04, 6:04PM CDT
What Shares of Keryx Biopharmaceuticals , a drug developer with a focus on renal disease, got a haircut during the month of July: The stock lost more than 18% of its value, according to data from S&P Capital IQ . During the month, Keryx...
KERX: 5.87 (+0.26)
5 Reasons to Buy Keryx Pharmaceuticals
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 04, 2:41PM CDT
The biotech sector has long been a great hunting ground for stocks that hold explosive growth potential. According to barchart, four of the five best performing stocks over the last 10 years have been biotechs. If you were smart (or lucky) enough to...
KERX: 5.87 (+0.26)
Will Keryx (KERX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 12:50PM CDT
Keryx (KERX) has an Earnings ESP of 0.00% with a Zacks Rank #4 and is scheduled to report its second-quarter 2015 results on Aug 5.
INO: 6.80 (+0.21), MYL: 51.13 (+2.02), EPZM: 17.52 (+0.48), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Shares Down 33.4% Since SmarTrend's Sell Call (KERX)
Comtex SmarTrend(R) - Tue Jul 28, 5:21PM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 33.44% as of today's recent price of $8.09.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015
GlobeNewswire - Tue Jul 28, 3:05PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, August 5, 2015 at 8:00 a.m. ET to discuss its second quarter 2015 financial results and provide a review of the Auryxia(TM) launch.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer
GlobeNewswire - Mon Jul 27, 7:06AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately. Mr. Holmes will be responsible for Keryx's finance function and will be a member of the company's executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Mr. Oliviero will stay with the company through a transition period.
KERX: 5.87 (+0.26)
Why Shares of Keryx Biopharmaceuticals Fell Today
Brian Feroldi, The Motley Fool - Motley Fool - Fri Jul 24, 3:16PM CDT
What: Shares of Keryx Biopharmaceuticals , a drug developer with a focus on renal disease, fell more than 15% today on heavy volume. So what: Keryx actually released some good news today as the company announced that the Committee...
KERX: 5.87 (+0.26)
Here's a One-of-a-Kind Stock Screen
at The Street - Wed Aug 19, 4:35PM CDT
And you don't even need a computer.
RST: 6.80 (+0.02), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Shares Down 50.3% Since SmarTrend's Sell Call (KERX)
Comtex SmarTrend(R) - Wed Aug 19, 11:10AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 5 months, Keryx Biopharmaceuticals has returned 50.27% as of today's recent price of $6.05.
KERX: 5.87 (+0.26)
4 Reasons to Sell Keryx Pharmaceuticals
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 18, 12:48PM CDT
For investors in Keryx Biopharmaceuticals (NASDAQ: KERX), a small-cap biotech with a focus on renal disease, 2015 hasn't been a good year, as its stock has plunged more than 50% since the start of the year. Despite being a company that holds ...
MS: 33.30 (+1.54), KERX: 5.87 (+0.26)
48.6% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Aug 12, 9:47AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 48.58% as of today's recent price of $6.25.
KERX: 5.87 (+0.26)
Downgrade Alert for Keryx Biopharmaceuticals (KERX)
Comtex SmarTrend(R) - Tue Aug 11, 7:00AM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $6.34 on volume of 2.4 million shares, above average daily volume of 1.8 million. Potential upside of 225.3% exists for Keryx Biopharmaceuticals, based on a current level of $6.34 and analysts' average consensus price target of $20.62. The stock should find initial resistance at its 50-day moving average (MA) of $9.30 and further resistance at its 200-day MA of $12.23.
KERX: 5.87 (+0.26)
Biotech Stock Mailbag: Controversial Stocks Revisited
at The Street - Fri Aug 07, 5:10AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RGLS: 7.20 (+0.42), RMTI: 11.58 (+0.43), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), KERX: 5.87 (+0.26)
Keryx Posts In-Line Loss in Q2, Auryxia in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 1:42PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) second-quarter 2015 loss of 26 cents per share was in line with the Zacks Consensus Estimate.
VRX: 227.24 (+7.16), ADHD: 7.84 (-0.02), ANAC: 132.24 (+6.60), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Has Returned 38.3% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Wed Aug 05, 9:23AM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 38.30% as of today's recent price of $7.50.
KERX: 5.87 (+0.26)
Biotechnology Stocks Technical Data -- Keryx Biopharma, Idera Pharma, Synthetic Biologics, OvaScience and Infinity Pharma
PR Newswire - Wed Aug 05, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Synthetic Biologics Inc. (AMEX: SYN), OvaScience Inc. (NASDAQ: OVAS) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Free research report on Keryx Biopharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=KERX. On Tuesday, August 04, 2015, the NASDAQ Composite ended at 5,105.55, down 0.19%, the Dow Jones Industrial Average lost 0.27%, to finish the day at 17,550.69 and the S&P 500 closed at 2,093.32, down 0.22%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SYN: 2.25 (+0.03), OVAS: 20.83 (+1.80), IDRA: 2.83 (+0.14), INFI: 8.87 (+0.38), KERX: 5.87 (+0.26)
Keryx's (KERX) Q2 Loss in-Line with Estimates - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 7:29AM CDT
Keryx's (KERX) Q2 Loss in-Line with Estimates
KERX: 5.87 (+0.26)
Keryx Biopharma reports 2Q loss
Automated Insights - Wed Aug 05, 6:18AM CDT
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Wednesday reported a loss of $26.9 million in its second quarter.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
GlobeNewswire - Wed Aug 05, 6:00AM CDT
Majority of phosphate binder patients today have access to Auryxia(TM)
KERX: 5.87 (+0.26)
Why Keryx Biopharmaceuticals Stock Plunged 18% in July
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 04, 6:04PM CDT
What Shares of Keryx Biopharmaceuticals , a drug developer with a focus on renal disease, got a haircut during the month of July: The stock lost more than 18% of its value, according to data from S&P Capital IQ . During the month, Keryx...
KERX: 5.87 (+0.26)
5 Reasons to Buy Keryx Pharmaceuticals
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 04, 2:41PM CDT
The biotech sector has long been a great hunting ground for stocks that hold explosive growth potential. According to barchart, four of the five best performing stocks over the last 10 years have been biotechs. If you were smart (or lucky) enough to...
KERX: 5.87 (+0.26)
Will Keryx (KERX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 12:50PM CDT
Keryx (KERX) has an Earnings ESP of 0.00% with a Zacks Rank #4 and is scheduled to report its second-quarter 2015 results on Aug 5.
INO: 6.80 (+0.21), MYL: 51.13 (+2.02), EPZM: 17.52 (+0.48), KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Shares Down 33.4% Since SmarTrend's Sell Call (KERX)
Comtex SmarTrend(R) - Tue Jul 28, 5:21PM CDT
SmarTrend identified a Downtrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 2nd, 2015 at $12.16. In approximately 4 months, Keryx Biopharmaceuticals has returned 33.44% as of today's recent price of $8.09.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015
GlobeNewswire - Tue Jul 28, 3:05PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, August 5, 2015 at 8:00 a.m. ET to discuss its second quarter 2015 financial results and provide a review of the Auryxia(TM) launch.
KERX: 5.87 (+0.26)
Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer
GlobeNewswire - Mon Jul 27, 7:06AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately. Mr. Holmes will be responsible for Keryx's finance function and will be a member of the company's executive team. He will succeed James Oliviero whose planned departure was announced earlier this year. Mr. Oliviero will stay with the company through a transition period.
KERX: 5.87 (+0.26)
Why Shares of Keryx Biopharmaceuticals Fell Today
Brian Feroldi, The Motley Fool - Motley Fool - Fri Jul 24, 3:16PM CDT
What: Shares of Keryx Biopharmaceuticals , a drug developer with a focus on renal disease, fell more than 15% today on heavy volume. So what: Keryx actually released some good news today as the company announced that the Committee...
KERX: 5.87 (+0.26)
